SOUTH PLAINFIELD, N.J., Nov. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of a no-cost testing program for aromatic L-amino acid decarboxylase (AADC) ...
SOUTH PLAINFIELD, N.J., Sept. 9, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new program that provides genetic testing and counseling for people who may have a ...
It’s a testing afternoon for investors who placed bets on Translarna, a drug for a rare form of muscular dystrophy. Shares in PTC Therapeutics, a small biotech group which is developing the medicine, ...
- Early diagnosis through genetic testing may lead to improved long-term outcomes for patients with neurotransmitter disorders, including AADC deficiency - "Genetic testing programs in rare disorders ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results